Merck reports positive Phase 2b results for efinopegdutide in MASH

Merck announced positive results from a Phase 2b trial of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage 2-3 fibrosis, showing meaningful improvement in liver fibrosis without worsening steatohepatitis. Results were presented at The Liver Meeting and published in The Lancet.

Detected & updated continuously · Source: Nebula